SL
UTHR icon

Sentinus LLC’s United Therapeutics UTHR Stock Holding History

Sentinus LLC’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$271K Sell
500
-8
-2% -$4.5K 0.02% 508
2026
Q1 		$301K Sell
508
-183
-26% -$91.1K 0.03% 423
2025
Q4 		$337K Buy
+691
New +$322K 0.03% 398

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Sentinus LLC's UTHR Position: Q2 2026 in Review

Sentinus LLC reduced its United Therapeutics (UTHR) stake by 1.6% in Q2 2026, selling an estimated $4.5K and leaving 500 shares worth $271K. The position accounts for 0.02% of the portfolio, ranked #508.

Sentinus LLC first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $337K in Q4 2025. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Sentinus LLC held 500 shares of United Therapeutics worth $271K as of Q2 2026.
  • Sentinus LLC sold 8 United Therapeutics shares in Q2 2026, an estimated $4.5K.
  • United Therapeutics made up 0.02% of Sentinus LLC's portfolio in Q2 2026, its #508 holding.
  • Sentinus LLC first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Sentinus LLC's United Therapeutics position peaked at $337K in Q4 2025.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Sentinus LLC's 13F filing for Q2 2026, filed 11 Aug 2026.